{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:32:42Z","timestamp":1774978362889,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T00:00:00Z","timestamp":1471478400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12888-016-1002-7","type":"journal-article","created":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T07:18:08Z","timestamp":1471504688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Psychosis associated with acute recreational drug toxicity: a European case series"],"prefix":"10.1186","volume":"16","author":[{"name":"Euro-DEN Research Group","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1213-392X","authenticated-orcid":false,"given":"Odd Martin","family":"Vallersnes","sequence":"first","affiliation":[]},{"given":"Alison M.","family":"Dines","sequence":"additional","affiliation":[]},{"given":"David M.","family":"Wood","sequence":"additional","affiliation":[]},{"given":"Christopher","family":"Yates","sequence":"additional","affiliation":[]},{"given":"Fridtjof","family":"Heyerdahl","sequence":"additional","affiliation":[]},{"given":"Knut Erik","family":"Hovda","sequence":"additional","affiliation":[]},{"given":"Isabelle","family":"Giraudon","sequence":"additional","affiliation":[]},{"given":"Paul I.","family":"Dargan","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,8,18]]},"reference":[{"key":"1002_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/bmj.39148.668160.80","volume":"334","author":"P Byrne","year":"2007","unstructured":"Byrne P. Managing the acute psychotic episode. BMJ. 2007;334:686\u201392.","journal-title":"BMJ."},{"key":"1002_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/1471-244X-12-221","volume":"12","author":"JG Bramness","year":"2012","unstructured":"Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Loberg EM, et al. Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry. 2012;12:221.","journal-title":"BMC Psychiatry."},{"key":"1002_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/08897077.2014.933726","volume":"35","author":"C Roncero","year":"2014","unstructured":"Roncero C, Daigre C, Grau-Lopez L, Barral C, Perez-Pazos J, Martinez-Luna N, et al. An international perspective and review of cocaine-induced psychosis: a call to action. Subst Abuse. 2014;35:321\u20137.","journal-title":"Subst Abuse."},{"key":"1002_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.comppsych.2008.07.009","volume":"50","author":"MJ Smith","year":"2009","unstructured":"Smith MJ, Thirthalli J, Abdallah AB, Murray RM, Cottler LB. Prevalence of psychotic symptoms in substance users: a comparison across substances. Comp Psychiatry. 2009;50:245\u201350.","journal-title":"Comp Psychiatry."},{"key":"1002_CR5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1176\/appi.ajp.162.4.774","volume":"162","author":"T Brugha","year":"2005","unstructured":"Brugha T, Singleton N, Meltzer H, Bebbington P, Farrell M, Jenkins R, et al. Psychosis in the community and in prisons: a report from the British National Survey of psychiatric morbidity. Am J Psychiatry. 2005;162:774\u201380.","journal-title":"Am J Psychiatry."},{"key":"1002_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/0004867412449877","volume":"46","author":"VA Morgan","year":"2012","unstructured":"Morgan VA, Waterreus A, Jablensky A, Mackinnon A, McGrath JJ, Carr V, et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012;46:735\u201352.","journal-title":"Aust N Z J Psychiatry."},{"key":"1002_CR7","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/j.1556-4029.2010.01441.x","volume":"55","author":"Z Mehmedic","year":"2010","unstructured":"Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, et al. Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010;55:1209\u201317.","journal-title":"J Forensic Sci."},{"key":"1002_CR8","volume-title":"European Drug Report 2015. Trends and developments","author":"European monitoring centre for drugs and drug addiction (EMCDDA)","year":"2015","unstructured":"European monitoring centre for drugs and drug addiction (EMCDDA). European Drug Report 2015. Trends and developments. Lisbon: EMCDDA; 2015."},{"key":"1002_CR9","volume-title":"EU drug markets report: a strategic analysis","author":"Europol and European monitoring centre for drugs and drug addiction (EMCDDA)","year":"2013","unstructured":"Europol and European monitoring centre for drugs and drug addiction (EMCDDA). EU drug markets report: a strategic analysis. Luxembourg: Publications office of the European Union; 2013."},{"key":"1002_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","volume":"2","author":"M Forti Di","year":"2015","unstructured":"Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. The Lancet Psychiatry. 2015;2:233\u20138.","journal-title":"The Lancet Psychiatry."},{"key":"1002_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1600-0447.1994.tb01541.x","volume":"89","author":"A Iwanami","year":"1994","unstructured":"Iwanami A, Sugiyama A, Kuroki N, Toda S, Kato N, Nakatani Y, et al. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatr Scand. 1994;89:428\u201332.","journal-title":"Acta Psychiatr Scand"},{"key":"1002_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3109\/09638237.2012.745184","volume":"22","author":"B Fasihpour","year":"2013","unstructured":"Fasihpour B, Molavi S, Shariat SV. Clinical features of inpatients with methamphetamine-induced psychosis. J Ment Health. 2013;22:341\u20139.","journal-title":"J Ment Health."},{"key":"1002_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1192\/bjp.187.6.510","volume":"187","author":"M Arendt","year":"2005","unstructured":"Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005;187:510\u20135.","journal-title":"Br J Psychiatry."},{"key":"1002_CR14","volume-title":"The challenge of new psychoactive substances: a report from the global SMART programme","author":"United Nations Office on Drugs and Crime (UNODC)","year":"2013","unstructured":"United Nations Office on Drugs and Crime (UNODC). The challenge of new psychoactive substances: a report from the global SMART programme. Vienna: UNODC; 2013."},{"key":"1002_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3109\/15563650.2011.615318","volume":"49","author":"SL Hill","year":"2011","unstructured":"Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol. 2011;49:705\u201319.","journal-title":"Clin Toxicol."},{"key":"1002_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/MEJ.0b013e3283573115","volume":"20","author":"DM Wood","year":"2013","unstructured":"Wood DM, Greene SL, Dargan PI. Five-year trends in self-reported recreational drugs associated with presentation to a UK emergency department with suspected drug-related toxicity. Eur J Emerg Med. 2013;20:263\u20137.","journal-title":"Eur J Emerg Med."},{"key":"1002_CR17","first-page":"139","volume":"111","author":"N Hohmann","year":"2014","unstructured":"Hohmann N, Mikus G, Czock D. Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals. Dtsch Arztebl Int. 2014;111:139\u201347.","journal-title":"Dtsch Arztebl Int."},{"key":"1002_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/15563650.2011.590812","volume":"49","author":"HA Spiller","year":"2011","unstructured":"Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of \"bath salts\" and \"legal highs\" (synthetic cathinones) in the United States. Clin Toxicol. 2011;49:499\u2013505.","journal-title":"Clin Toxicol."},{"key":"1002_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","volume":"144","author":"MS Castaneto","year":"2014","unstructured":"Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12\u201341.","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"1002_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s13181-013-0306-y","volume":"9","author":"WL Chan","year":"2013","unstructured":"Chan WL, Wood DM, Hudson S, Dargan PI. Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis. J Med Toxicol. 2013;9(3):278\u201381.","journal-title":"J Med Toxicol"},{"key":"1002_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/hup.2312","volume":"28","author":"D Papanti","year":"2013","unstructured":"Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, et al. \u201cSpiceophrenia\u201d: a systematic overview of \u201cspice\u201d-related psychopathological issues and a case report. Hum Psychopharmacol. 2013;28:379\u201389.","journal-title":"Hum Psychopharmacol."},{"key":"1002_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3109\/15563650.2012.716158","volume":"50","author":"DM Wood","year":"2012","unstructured":"Wood DM, Dargan PI. Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP). Clin Toxicol. 2012;50:727\u201332.","journal-title":"Clin Toxicol."},{"key":"1002_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.annemergmed.2012.03.007","volume":"60","author":"CO Hoyte","year":"2012","unstructured":"Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012;60:435\u20138.","journal-title":"Ann Emerg Med."},{"key":"1002_CR24","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1177\/0960327111421945","volume":"31","author":"MB Forrester","year":"2012","unstructured":"Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol. 2012;31:1006\u201311.","journal-title":"Hum Exp Toxicol."},{"key":"1002_CR25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/emj.2010.096636","volume":"28","author":"D James","year":"2011","unstructured":"James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, et al. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons information service. Emerg Med J. 2011;28:686\u20139.","journal-title":"Emerg Med J"},{"key":"1002_CR26","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3109\/15563650.2014.973115","volume":"52","author":"A Kamour","year":"2014","unstructured":"Kamour A, James D, Lupton DJ, Cooper G, Eddleston M, Vale A, et al. Patterns of presentation and clinical features of toxicity after reported use of ([2-aminopropyl]-2,3-dihydrobenzofurans), the \u2018benzofuran\u2019 compounds. A report from the United Kingdom National Poisons Information Service. Clin Toxicol. 2014;52:1025\u201331.","journal-title":"Clin Toxicol"},{"key":"1002_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/15563650.2014.885983","volume":"52","author":"A Kamour","year":"2014","unstructured":"Kamour A, James D, Spears R, Cooper G, Lupton DJ, Eddleston M, et al. Patterns of presentation and clinical toxicity after reported use of alpha methyltryptamine in the United Kingdom. A report from the UK national poisons information service. Clin Toxicol. 2014;52:192\u20137.","journal-title":"Clin Toxicol"},{"key":"1002_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13181-014-0446-8","volume":"11","author":"BA Froberg","year":"2015","unstructured":"Froberg BA, Levine M, Beuhler MC, Judge BS, Moore PW, Engebretsen KM, et al. Acute methylenedioxypyrovalerone toxicity. J Med Toxicol. 2015;11:185\u201394.","journal-title":"J Med Toxicol."},{"key":"1002_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/15563650.2014.898771","volume":"52","author":"DM Wood","year":"2014","unstructured":"Wood DM, Heyerdahl F, Yates CB, Dines AM, Giraudon I, Hovda KE, et al. The European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2014;52:239\u201341.","journal-title":"Clin Toxicol."},{"key":"1002_CR30","unstructured":"Sergeant ESG. Epitools epidemiological calculators. AusVet Animal Health Services and Australian Biosecurity Cooperative Research Centre for Emerging Infectious Disease. 2016. http:\/\/epitools.ausvet.com.au. Accessed 8 Jan 2016"},{"key":"1002_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.psychres.2012.09.023","volume":"206","author":"S Medhus","year":"2013","unstructured":"Medhus S, Mordal J, Holm B, Morland J, Bramness JG. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry Res. 2013;206:17\u201321.","journal-title":"Psychiatry Res."},{"key":"1002_CR32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.pnpbp.2011.01.014","volume":"35","author":"M Srisurapanont","year":"2011","unstructured":"Srisurapanont M, Arunpongpaisal S, Wada K, Marsden J, Ali R, Kongsakon R. Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Progr Neuropsychopharmacol Biol Psychiatry. 2011;35:959\u201364.","journal-title":"Progr Neuropsychopharmacol Biol Psychiatry."},{"key":"1002_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb05178.x","volume":"914","author":"K Yui","year":"2000","unstructured":"Yui K, Ikemoto S, Ishiguro T, Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Ann N Y Acad Sci. 2000;914:1\u201312.","journal-title":"Ann N Y Acad Sci."},{"key":"1002_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1176\/appi.ajp.2011.10070937","volume":"169","author":"RC Callaghan","year":"2012","unstructured":"Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry. 2012;169:389\u201396.","journal-title":"Am J Psychiatry."},{"key":"1002_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4088\/JCP.v69n0304","volume":"69","author":"S Mathias","year":"2008","unstructured":"Mathias S, Lubman DI, Hides L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry. 2008;69:358\u201367.","journal-title":"J Clin Psychiatry."},{"key":"1002_CR36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/archpsyc.62.9.975","volume":"62","author":"M Marshall","year":"2005","unstructured":"Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975\u201383.","journal-title":"Arch Gen Psychiatry."},{"key":"1002_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/schbul\/sbr110","volume":"37","author":"M Marshall","year":"2011","unstructured":"Marshall M, Rathbone J. Early intervention for psychosis. Schizophr Bull. 2011;37:1111\u20134.","journal-title":"Schizophr Bull."},{"key":"1002_CR38","doi-asserted-by":"publisher","first-page":"f185","DOI":"10.1136\/bmj.f185","volume":"346","author":"MR Stafford","year":"2013","unstructured":"Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ. 2013;346:f185.","journal-title":"BMJ."},{"key":"1002_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1176\/appi.ajp.2011.11030459","volume":"169","author":"WT Hegelstad","year":"2012","unstructured":"Hegelstad WT, Larsen TK, Auestad B, Evensen J, Haahr U, Joa I, et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry. 2012;169:374\u201380.","journal-title":"Am J Psychiatry."},{"key":"1002_CR40","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","volume":"29","author":"DC D'Souza","year":"2004","unstructured":"D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol. 2004;29:1558\u201372.","journal-title":"Neuropsychopharmacol."},{"key":"1002_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/B978-0-12-415816-0.00015-8","volume-title":"Novel psychoactive substances: classification, pharmacology and toxicology","author":"SL Greene","year":"2013","unstructured":"Greene SL. Tryptamines. In: Dargan PI, Wood DM, editors. Novel psychoactive substances: classification, pharmacology and toxicology. London: Academic press; 2013. p. 363\u201381."},{"key":"1002_CR42","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","volume":"108","author":"M Hermanns-Clausen","year":"2013","unstructured":"Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108:534\u201344.","journal-title":"Addiction."},{"key":"1002_CR43","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1136\/emj.2010.103093","volume":"28","author":"L Regan","year":"2011","unstructured":"Regan L, Mitchelson M, Macdonald C. Mephedrone toxicity in a Scottish emergency department. Emerg Med J. 2011;28:1055\u20138.","journal-title":"Emerg Med J."},{"key":"1002_CR44","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3109\/15563650.2010.531021","volume":"48","author":"DM Wood","year":"2010","unstructured":"Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol. 2010;48:924\u20137.","journal-title":"Clin Toxicol."},{"key":"1002_CR45","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/WNF.0b013e3181e29174","volume":"33","author":"M Kraemer","year":"2010","unstructured":"Kraemer M, Uekermann J, Wiltfang J, Kis B. Methylphenidate-induced psychosis in adult attention-deficit\/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol. 2010;33:204\u20136.","journal-title":"Clin Neuropharmacol."},{"key":"1002_CR46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1017\/neu.2014.45","volume":"27","author":"KJ Chen","year":"2015","unstructured":"Chen KJ, Lu ML, Shen WW. Tramadol-related psychosis in a patient with bipolar I disorder. Acta Neuropsychiatr. 2015;27:126\u20138.","journal-title":"Acta Neuropsychiatr."},{"key":"1002_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/0269881105049040","volume":"19","author":"DM Semple","year":"2005","unstructured":"Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19:187\u201394.","journal-title":"J Psychopharmacol."},{"key":"1002_CR48","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.cpr.2006.09.004","volume":"27","author":"L Gregg","year":"2007","unstructured":"Gregg L, Barrowclough C, Haddock G. Reasons for increased substance use in psychosis. Clin Psychol Rev. 2007;27:494\u2013510.","journal-title":"Clin Psychol Rev."},{"key":"1002_CR49","unstructured":"European monitoring centre for drugs and drug addiction (EMCDDA). Key epidemiological indicators. \n                    http:\/\/www.emcdda.europa.eu\/activities\/key-indicators\n                    \n                  . Accessed 9 Sept 2015."},{"key":"1002_CR50","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3109\/15563650.2014.976792","volume":"52","author":"F Heyerdahl","year":"2014","unstructured":"Heyerdahl F, Hovda KE, Giraudon I, Yates C, Dines AM, Sedefov R, et al. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations. Clin Toxicol. 2014;52:1005\u201312.","journal-title":"Clin Toxicol."},{"key":"1002_CR51","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3109\/15563650.2015.1088157","volume":"53","author":"AM Dines","year":"2015","unstructured":"Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2015;53:893\u2013900.","journal-title":"Clin Toxicol."}],"updated-by":[{"DOI":"10.1186\/s12888-016-1066-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T00:00:00Z","timestamp":1479254400000}}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-016-1002-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-016-1002-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-016-1002-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-016-1002-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T17:20:21Z","timestamp":1487697621000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-016-1002-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,18]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1186\/s12888-016-1002-7","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12888-016-1066-4","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,18]]},"article-number":"293"}}